Commercial
Top 5 pharma news stories of 2014
It’s been an eventful and promising year for pharma. The eyeforpharma team choose their top five pharma news stories of 2014.
More Access and Evidence Articles
Commercial
Mental health in developing countries: How pharma can help
Mental illnesses affect hundreds of millions of people in the developing world, incurring high economic and social costs, yet they remain hugely under-resourced. Here we explore how pharma can help to change that.
Access and Evidence
Right to Try Act
Called the “right to beg” by its critics, the Right to Try Act allows patients who have come to the end of the road to seek treatment without FDA approval.
Access and Evidence
How the multi-disciplinary organization of the future will succeed in access and approval
Aidan Brain recently spoke with Adam Hacker, Vice President, EMEA Therapeutic Area Leader, Hematology & Oncology at Janssen, to discuss the European Commission’s approval of marketing authorization for IMBRUVICA™ (ibrutinib) capsules in the EU in two forms of blood cancer - MCL and CLL.
Access and Evidence
The impact of value misalignment on patient outcomes
Biopharma's success in the new healthcare economy is focused on a clear guiding principle: prove the value of the product to all stakeholders, or risk commercial failure.
Commercial
Partners in Integrated Healthcare: Evolving to a Solutions-Based Model
Becoming partners in integrated healthcare will require intense collaboration by pharma both internally across functions and externally with non-traditional entrants. eyeforpharma talks to Marco Mohwinckel about some of the inherent challenges of evolving to a solutions-based model.
Commercial
Getting to grips with Russia’s healthcare market
As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't exist.
Access and Evidence
Separating "science" from "sales"
Changing market dynamics and recent problems relating to Investigator Initiated Trials mean that the Medical Affairs function is becoming increasingly influential within the pharma sector in Japan. Nick de Cent talks to Dr Sumu Adachi, Medical Director at AbbVie in Japan.
Access and Evidence
Thinking outside the pillbox
Poor medication adherence is a source of significant waste in our healthcare system. Investing in smart technologies is much cheaper than risking patient non-compliance.